Skip to main content
Erschienen in: Rheumatology International 1/2021

26.10.2020 | Observational Research

Inflammatory milieu of muscle biopsies in juvenile dermatomyositis

verfasst von: Erdal Sag, Gulsev Kale, Goknur Haliloglu, Yelda Bilginer, Zuhal Akcoren, Diclehan Orhan, Safak Gucer, Haluk Topaloglu, Seza Ozen, Beril Talim

Erschienen in: Rheumatology International | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Juvenile dermatomyositis (JDM) is an inflammatory myopathy which causes severe morbidity and high mortality if untreated. In this study, we aimed to define the T-helper cell profile in the muscle biopsies of JDM patients. Muscle biopsies of twenty-six patients (50% female) were included in the study. Immunohistochemical expression of CD3, CD20, CD138, CD68, IL-17, Foxp3, IFN-ɣ, IFN-alpha and IL-4 was studied and muscle biopsies were scored using the JDM muscle biopsy scoring tool. Inflammatory cells were in small clusters in perimysium and perivascular area or scattered throughout the endomysium in most biopsies; however in 2 biopsies, lymphoid follicle-like big clusters were observed, and in one, there was a very dense and diffuse inflammatory infiltration nearly destroying all the muscle architecture. Seventy-three per cent of the biopsies had T cells, 88% had B cells, 57% had plasma cells, and all had macrophages. As for T-helper cell subtypes, 80% of the biopsies were Th1 positive, 92% Th17 positive and 30% Treg positive. No IL-4 positive inflammatory cell was detected, and only 2 biopsies showed IFN-alpha positivity. The mean JDM biopsy score was 17.6, meaning moderate to severe muscular involvement. Visual analogue score of the pathologist was strongly correlated with histopathological features. B cells, macrophages, plasma cells and T cells constitute the inflammatory milieu of the JDM muscle biopsies. As for T cells, JDM is a disease mainly related with Th1 and Th17 T-helper cell subtypes and to some extend Treg. Th2 cells are not involved in the pathogenesis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Wedderburn LR, Rider LG (2009) Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol 23(5):665–678PubMedPubMedCentral Wedderburn LR, Rider LG (2009) Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol 23(5):665–678PubMedPubMedCentral
2.
Zurück zum Zitat Unverricht H (1891) Dermatomyositis acuta. DTsch Med Wochenschr 17:41–44 Unverricht H (1891) Dermatomyositis acuta. DTsch Med Wochenschr 17:41–44
3.
Zurück zum Zitat Bohan A, Peter JB (1975a) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292(8):403–407PubMed Bohan A, Peter JB (1975a) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292(8):403–407PubMed
4.
Zurück zum Zitat Bohan A, Peter JB (1975b) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–347PubMed Bohan A, Peter JB (1975b) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–347PubMed
5.
Zurück zum Zitat Robinson AB, Reed AM (2011) Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol 7(11):664–675PubMed Robinson AB, Reed AM (2011) Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol 7(11):664–675PubMed
6.
Zurück zum Zitat Li CK et al (2004) MHC Class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol 31(3):605–609PubMed Li CK et al (2004) MHC Class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol 31(3):605–609PubMed
7.
Zurück zum Zitat Chevrel G et al (2003) Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol 137(1–2):125–133PubMed Chevrel G et al (2003) Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol 137(1–2):125–133PubMed
8.
Zurück zum Zitat de Padilla CML et al (2007) Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum 56(5):1658–1668 de Padilla CML et al (2007) Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum 56(5):1658–1668
9.
Zurück zum Zitat Baechler EC, Bilgic H, Reed AM (2011) Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther 13(6):249PubMedPubMedCentral Baechler EC, Bilgic H, Reed AM (2011) Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther 13(6):249PubMedPubMedCentral
10.
Zurück zum Zitat Kao L, Chung L, Fiorentino DF (2011) Pathogenesis of dermatomyositis: role of cytokines and interferon. Curr Rheumatol Rep 13(3):225–232PubMed Kao L, Chung L, Fiorentino DF (2011) Pathogenesis of dermatomyositis: role of cytokines and interferon. Curr Rheumatol Rep 13(3):225–232PubMed
11.
Zurück zum Zitat Salomonsson S, Lundberg IE (2006) Cytokines in idiopathic inflammatory myopathies. Autoimmunity 39(3):177–190PubMed Salomonsson S, Lundberg IE (2006) Cytokines in idiopathic inflammatory myopathies. Autoimmunity 39(3):177–190PubMed
12.
Zurück zum Zitat Lundberg I et al (1997) Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 40(5):865–874PubMed Lundberg I et al (1997) Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 40(5):865–874PubMed
13.
Zurück zum Zitat Soponkanaporn S et al (2019) Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis. Neuropathol Appl Neurobiol 45(4):410–420PubMed Soponkanaporn S et al (2019) Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis. Neuropathol Appl Neurobiol 45(4):410–420PubMed
14.
Zurück zum Zitat Jager A, Kuchroo VK (2010) Effector and regulatory T-cell subsets in autoimmunity and tissue inflammation. Scand J Immunol 72(3):173–184PubMedPubMedCentral Jager A, Kuchroo VK (2010) Effector and regulatory T-cell subsets in autoimmunity and tissue inflammation. Scand J Immunol 72(3):173–184PubMedPubMedCentral
15.
Zurück zum Zitat Palmer MT, Weaver CT (2010) Autoimmunity: increasing suspects in the CD4+ T cell lineup. Nat Immunol 11(1):36–40PubMed Palmer MT, Weaver CT (2010) Autoimmunity: increasing suspects in the CD4+ T cell lineup. Nat Immunol 11(1):36–40PubMed
16.
Zurück zum Zitat Steinman L (2010) Mixed results with modulation of TH-17 cells in human autoimmune diseases. Nat Immunol 11(1):41–44PubMed Steinman L (2010) Mixed results with modulation of TH-17 cells in human autoimmune diseases. Nat Immunol 11(1):41–44PubMed
17.
Zurück zum Zitat Wedderburn LR et al (2007) International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum 57(7):1192–1201PubMed Wedderburn LR et al (2007) International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum 57(7):1192–1201PubMed
18.
Zurück zum Zitat Varsani H et al (2015) Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease. Ann Rheum Dis 74(1):204–210PubMed Varsani H et al (2015) Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease. Ann Rheum Dis 74(1):204–210PubMed
19.
Zurück zum Zitat Deakin CT et al (2016) Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis. Arthritis Rheumatol 68(11):2806–2816PubMedPubMedCentral Deakin CT et al (2016) Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis. Arthritis Rheumatol 68(11):2806–2816PubMedPubMedCentral
20.
Zurück zum Zitat Yasin SA et al (2019) Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features. Neuropathol Appl Neurobiol 45(5):495–512PubMedPubMedCentral Yasin SA et al (2019) Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features. Neuropathol Appl Neurobiol 45(5):495–512PubMedPubMedCentral
21.
Zurück zum Zitat Tansley SL et al (2014) Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther 16(4):R138PubMedPubMedCentral Tansley SL et al (2014) Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther 16(4):R138PubMedPubMedCentral
22.
Zurück zum Zitat Lopez De Padilla CM et al (2009) Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum 60(4):1160–1172PubMed Lopez De Padilla CM et al (2009) Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum 60(4):1160–1172PubMed
23.
Zurück zum Zitat Oddis CV et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65(2):314–324PubMedPubMedCentral Oddis CV et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65(2):314–324PubMedPubMedCentral
24.
Zurück zum Zitat Bader-Meunier B et al (2011) Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol 38(7):1436–1440PubMed Bader-Meunier B et al (2011) Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol 38(7):1436–1440PubMed
25.
Zurück zum Zitat Bellutti Enders F et al (2017) Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis 76(2):329–340PubMed Bellutti Enders F et al (2017) Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis 76(2):329–340PubMed
26.
Zurück zum Zitat Aggarwal R et al (2014) Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 66(3):740–749PubMedPubMedCentral Aggarwal R et al (2014) Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 66(3):740–749PubMedPubMedCentral
27.
Zurück zum Zitat Hamaguchi Y et al (2011) Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 147(4):391–398PubMed Hamaguchi Y et al (2011) Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 147(4):391–398PubMed
28.
Zurück zum Zitat Shah M et al (2013) The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92(1):25–41 Shah M et al (2013) The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92(1):25–41
29.
Zurück zum Zitat Stone KB et al (2007) Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 56(9):3125–3131PubMed Stone KB et al (2007) Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 56(9):3125–3131PubMed
30.
Zurück zum Zitat Bilgic H et al (2009) Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 60(11):3436–3446PubMed Bilgic H et al (2009) Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 60(11):3436–3446PubMed
31.
Zurück zum Zitat Baechler EC et al (2007) An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 13(1–2):59–68PubMedPubMedCentral Baechler EC et al (2007) An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 13(1–2):59–68PubMedPubMedCentral
32.
Zurück zum Zitat Salajegheh M et al (2010) Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 67(1):53–63PubMedPubMedCentral Salajegheh M et al (2010) Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 67(1):53–63PubMedPubMedCentral
33.
Zurück zum Zitat Chinoy H et al (2007) Interferon-gamma and interleukin-4 gene polymorphisms in Caucasian idiopathic inflammatory myopathy patients in UK. Ann Rheum Dis 66(7):970–973PubMedPubMedCentral Chinoy H et al (2007) Interferon-gamma and interleukin-4 gene polymorphisms in Caucasian idiopathic inflammatory myopathy patients in UK. Ann Rheum Dis 66(7):970–973PubMedPubMedCentral
34.
Zurück zum Zitat De Rossi M et al (2000) Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. Int Immunol 12(9):1329–1335PubMed De Rossi M et al (2000) Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. Int Immunol 12(9):1329–1335PubMed
35.
Zurück zum Zitat Jager A et al (2009) Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol 183(11):7169–7177PubMedPubMedCentral Jager A et al (2009) Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol 183(11):7169–7177PubMedPubMedCentral
36.
37.
Zurück zum Zitat Crowson CS et al (2019) Interferon chemokine score and other cytokine measures track with changes in disease activity in patients with juvenile and adult dermatomyositis. ACR Open Rheumatol 1(2):83–89PubMedPubMedCentral Crowson CS et al (2019) Interferon chemokine score and other cytokine measures track with changes in disease activity in patients with juvenile and adult dermatomyositis. ACR Open Rheumatol 1(2):83–89PubMedPubMedCentral
38.
Zurück zum Zitat Coates LC et al (2016) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68(5):1060–1071PubMed Coates LC et al (2016) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68(5):1060–1071PubMed
39.
Zurück zum Zitat Baeten D et al (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382(9906):1705–1713PubMed Baeten D et al (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382(9906):1705–1713PubMed
40.
Zurück zum Zitat Bettelli E et al (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441(7090):235–238PubMed Bettelli E et al (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441(7090):235–238PubMed
41.
Zurück zum Zitat Vercoulen Y et al (2014) Increased presence of FOXP3+ regulatory T cells in inflamed muscle of patients with active juvenile dermatomyositis compared to peripheral blood. PLoS ONE 9(8):e105353PubMedPubMedCentral Vercoulen Y et al (2014) Increased presence of FOXP3+ regulatory T cells in inflamed muscle of patients with active juvenile dermatomyositis compared to peripheral blood. PLoS ONE 9(8):e105353PubMedPubMedCentral
42.
Zurück zum Zitat Fujiyama T et al (2014) Preferential infiltration of interleukin-4-producing CXCR4+ T cells in the lesional muscle but not skin of patients with dermatomyositis. Clin Exp Immunol 177(1):110–120PubMedPubMedCentral Fujiyama T et al (2014) Preferential infiltration of interleukin-4-producing CXCR4+ T cells in the lesional muscle but not skin of patients with dermatomyositis. Clin Exp Immunol 177(1):110–120PubMedPubMedCentral
43.
Zurück zum Zitat Horsley V et al (2003) IL-4 acts as a myoblast recruitment factor during mammalian muscle growth. Cell 113(4):483–494PubMed Horsley V et al (2003) IL-4 acts as a myoblast recruitment factor during mammalian muscle growth. Cell 113(4):483–494PubMed
Metadaten
Titel
Inflammatory milieu of muscle biopsies in juvenile dermatomyositis
verfasst von
Erdal Sag
Gulsev Kale
Goknur Haliloglu
Yelda Bilginer
Zuhal Akcoren
Diclehan Orhan
Safak Gucer
Haluk Topaloglu
Seza Ozen
Beril Talim
Publikationsdatum
26.10.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 1/2021
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-020-04735-w

Weitere Artikel der Ausgabe 1/2021

Rheumatology International 1/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.